☆ 4.7 Editorial Material

Advances in Diagnosis and Prognosis of Parkinson Disease

NEUROLOGY (2023)

Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study

Andrew Siderowf et al.

LANCET NEUROLOGY (2023)

添加到收藏夹

Article Clinical Neurology

High-Throughput CSF Proteomics and Machine Learning to Identify Proteomic Signatures for Parkinson Disease Development and Progression

Kazuto Tsukita et al.

Summary: By combining high-throughput proteomics with machine learning, we identified CSF proteomic signatures characteristic of Parkinson disease (PD) that are crucial for PD development and progression. These signatures have clinical utility in the diagnosis and prediction of PD.

NEUROLOGY (2023)

添加到收藏夹

Review Clinical Neurology

alpha-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies The Way Forward

Giovanni Bellomo et al.

Summary: Parkinson disease (PD) is a common neurodegenerative disease associated with misfolding and aggregation of alpha-synuclein. Seed amplification assays (SAAs) can detect misfolded alpha-synuclein in patients with PD and are promising diagnostic biomarkers. However, standardization issues need to be addressed.

NEUROLOGY (2022)

添加到收藏夹

Article Cell Biology

CSF proteome profiling across the Alzheimer's disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels

Marta del Campo et al.

Summary: This study identifies specific dysregulated CSF proteins along the AD continuum, reflecting the multifactorial nature of disease progression. Some of these dysregulated proteins can be used as biomarkers for the diagnosis and clinical trials of AD.

NATURE AGING (2022)

添加到收藏夹

Review Clinical Neurology

a-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies The Way Forward

Giovanni Bellomo et al.

Summary: Parkinson's disease is the second most common neurodegenerative disease, and its diagnosis is currently based on motor symptoms. Seed amplification assays have the potential to identify Parkinson's disease at an earlier stage.

NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology

Martina Sattlecker et al.

ALZHEIMERS & DEMENTIA (2014)

添加到收藏夹

Review Neurosciences

The Parkinson Progression Marker Initiative (PPMI)

Kenneth Marek et al.

PROGRESS IN NEUROBIOLOGY (2011)

添加到收藏夹

Advances in Diagnosis and Prognosis of Parkinson Disease

相关参考文献

Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study

High-Throughput CSF Proteomics and Machine Learning to Identify Proteomic Signatures for Parkinson Disease Development and Progression

alpha-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies The Way Forward

CSF proteome profiling across the Alzheimer's disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels

a-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies The Way Forward

Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology

The Parkinson Progression Marker Initiative (PPMI)

导出引文

分享论文